Enhancing Cognitive Reserve of the Offsprings of Bipolar and Schizophrenic Patients
NCT03722082, Not applicable, Unknown, Hospital Clinic of Barcelona
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Enhancing Cognitive Reserve of the Offsprings of Bipolar and Schizophrenic Patients | ClinicalTrials.gov |
| NCT number | NCT03722082 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 173 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Hospital Clinic of Barcelona | ClinicalTrials.gov |
| Conditions | Bipolar and Related Disorders | ClinicalTrials.gov |
| Interventions | Enhancing Cognitive Reserve, Support intervention | ClinicalTrials.gov |
| First posted | 2018-10-26 | ClinicalTrials.gov |
| Last updated | 2022-05-05 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Cognitive reserve | 3 months afther the intervention and 12 months after baseline | Changes in cognitive reserve assessed with a specific scale which assesses the most common proposed proxy indicators such as education-occupation' which is assessed taking into account the number of years of obligatory education that subjects completed and parent's educational level; and the lifetime school performance and lifetime participation in leisure, social and physical activities. | ClinicalTrials.gov |
| Secondary | Hamilton Depression Rating Scale (HDRS-21) | After the intervention (3 months) and 1 year after baseline | Scale to assess depression symptoms. Score between 0 to 7 indicates absence of depressive symptoms, hihher scores indicate more severe depression. | ClinicalTrials.gov |
| Secondary | Young Mania Rating Scale (YMRS) | After the intervention (3 months) and 1 year after baseline | The YMRS is a rating scale used to evaluate manic symptoms at baseline and over time in individuals with mania. Scores superior to 12 indicate presence of manic episodes. Higher scores indicate more severe mania. | ClinicalTrials.gov |
| Secondary | Bipolar Prodrome Symptom Interview and Scale_Prospective (BPSS_FP) | 12 months after baseline | It is a specific interview for emerging bipolar disorder symptoms. | ClinicalTrials.gov |
| Secondary | Continuous Performance Test | After the intervention (3 months) and 12 months after baseline | Sustained attention test | ClinicalTrials.gov |
| Secondary | Wisconsin Card Sorting Test | After the intervention (3 months) and 12 months after baseline | Executive function test (set-shifting, flexibility) | ClinicalTrials.gov |
| Secondary | Stroop Test | After the intervention (3 months) and 12 months after baseline | Executive function test (inhibit interference) | ClinicalTrials.gov |
| Secondary | Neuroimage variables | After the intervention (3 months) | Changes in white and grey matter. Measure will be performed with a MRI | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 33631372 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Card Sorting Test (Berg) | Secondary outcome | ConductCognition |
| Continuous Performance Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)